Ozempic vs. Mounjaro vs. Wegovy vs. Zepbound: What Is the Difference?

Ozempic, Mounjaro, Wegovy, and Zepbound are often discussed as though they are four versions of the same medication. They are related, but they are not interchangeable copies.

Two contain semaglutide. Two contain tirzepatide. Some are approved primarily for type 2 diabetes, while others are approved for chronic weight management and additional conditions. The correct choice depends on the diagnosis, age, medical history, treatment goals, insurance coverage, preferred formulation, and ability to tolerate treatment.

This guide compares the medications using their current U.S. prescribing information as of July 2026.

Quick Comparison

Ozempic and Wegovy Contain the Same Active Ingredient

Ozempic and Wegovy both contain semaglutide, a GLP-1 receptor agonist.

GLP-1 is a hormone involved in blood-glucose regulation, appetite, food intake, and gastric emptying. Semaglutide activates GLP-1 receptors, which can improve glucose control and reduce appetite.

Having the same active ingredient does not make the products interchangeable. They may have different FDA-approved uses, dosage strengths, dose-escalation schedules, maintenance doses, formulations, insurance requirements, and packaging and administration instructions.

A patient should not switch between Ozempic and Wegovy without instructions from the prescribing healthcare professional.

Mounjaro and Zepbound Contain the Same Active Ingredient

Mounjaro and Zepbound both contain tirzepatide, which activates two hormone receptors: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).

Mounjaro is the diabetes brand. Zepbound is the brand approved for chronic weight management and obstructive sleep apnea in qualifying adults.

Although the active ingredient is the same, the diagnosis, product labeling, insurance coverage, and treatment plan may differ. These products should not be swapped casually or used together.

What Is Ozempic Approved For?

Current U.S. labeling includes both Ozempic injection and Ozempic tablets. Ozempic is used with diet and exercise to improve glycemic control in adults with type 2 diabetes.

Ozempic injection is also approved to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of sustained decline in kidney function, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.¹

Ozempic tablets are also approved to reduce the risk of major cardiovascular events in adults with type 2 diabetes who are at high risk for those events.

Ozempic is not FDA-approved as a chronic weight-management medication. Some patients lose weight while taking it, but its approved role should not be confused with Wegovy's weight-management indication.

Dosing overview: Ozempic injection starts at 0.25 mg once weekly, with a maximum labeled dose of 2 mg once weekly. Ozempic tablets are taken once daily on an empty stomach in the morning with no more than four ounces of water, waiting at least 30 minutes before eating, drinking other beverages, or taking other oral medications. Labeled tablet strengths include 1.5 mg, 4 mg, and 9 mg.

What Is Mounjaro Approved For?

Mounjaro is approved, along with diet and exercise, to improve glycemic control in adults with type 2 diabetes and pediatric patients 10 years of age and older with type 2 diabetes.³

Dosing overview: Mounjaro is a once-weekly injection starting at 2.5 mg. After four weeks, the dose is generally increased to 5 mg once weekly, with additional increases in 2.5 mg increments after at least four weeks at the current dose. The current maximum labeled dose is 15 mg once weekly for adults and 10 mg once weekly for pediatric patients 10 and older.

Mounjaro is not FDA-approved under that brand name for chronic weight management. Tirzepatide used for that purpose is marketed as Zepbound.

What Is Wegovy Approved For?

Wegovy is the semaglutide brand with weight-management indications. Wegovy injection is approved with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain long-term weight reduction in adults with obesity or with overweight and at least one weight-related condition, to treat obesity in pediatric patients 12 years and older, to reduce cardiovascular risk in adults with established cardiovascular disease and obesity or overweight, and to treat noncirrhotic MASH with moderate to advanced fibrosis in adults under the accelerated-approval pathway.²

Wegovy tablets are approved for chronic weight management and cardiovascular risk reduction in qualifying adults. The tablet formulation is not labeled for pediatric obesity or MASH.

Dosing overview: Wegovy injection starts at 0.25 mg once weekly, with a usual maintenance dose of 2.4 mg once weekly depending on indication and tolerability. Wegovy tablets start at 1.5 mg daily and advance toward a 25 mg daily maintenance dose, taken on an empty stomach with up to four ounces of water and a 30-minute wait before food, beverages, or other oral medications.

What Is Zepbound Approved For?

Zepbound is the tirzepatide brand approved for chronic weight management. It is used with a reduced-calorie diet and increased physical activity to reduce and maintain long-term weight loss in adults with obesity or overweight plus a weight-related condition, and to treat moderate-to-severe obstructive sleep apnea in adults with obesity.⁴

Dosing overview: Zepbound is a once-weekly injection starting at 2.5 mg for four weeks, then increased in 2.5 mg increments after at least four weeks at the current dose. Labeled maintenance doses are 5, 10, or 15 mg weekly for weight reduction, and 10 or 15 mg weekly for obstructive sleep apnea. The maximum recommended dose is 15 mg once weekly.

Which Medication Is Approved for Weight Loss?

The brands specifically approved for chronic weight management are Wegovy and Zepbound.

Ozempic and Mounjaro may produce weight loss in some patients, but they are diabetes brands and are not FDA-approved under those names for chronic weight management.

This distinction matters because insurance plans commonly evaluate the diagnosis, product, and benefit category separately. A plan may cover a diabetes medication while excluding weight-management medication, or it may require different prior authorization criteria for each indication.

Which Medication Produces More Weight Loss?

A 72-week head-to-head trial (SURMOUNT-5) compared once-weekly tirzepatide with once-weekly semaglutide in 751 adults with obesity who did not have type 2 diabetes. Participants received their maximum tolerated dose of tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg).

Average weight reduction at week 72 was 20.2% with tirzepatide versus 13.7% with semaglutide. Tirzepatide also produced a greater average reduction in waist circumference. Gastrointestinal side effects were the most common adverse events in both groups and occurred mainly during dose escalation.⁵

This study does not mean Zepbound is automatically the best medication for every patient. It involved a specific population, used maximum tolerated injection doses, excluded people with diabetes, and measured average results. Individual response, safety, coverage, and treatment goals remain important.

Which Medication Is Better for Type 2 Diabetes?

For type 2 diabetes, the direct brand comparison is usually Ozempic versus Mounjaro. Both improve blood-glucose control, but they differ in mechanism, dosing options, age approval, cardiovascular and kidney indications, side-effect experience, and insurance coverage.

Mounjaro is approved for patients 10 years and older with type 2 diabetes, while Ozempic is approved for adults only. Ozempic offers weekly injection and daily tablet formulations; Mounjaro is a weekly injection only. Ozempic injection also has labeled cardiovascular and chronic-kidney-disease risk-reduction indications in qualifying adults, while Mounjaro's current label focuses on glycemic control.

The prescriber may consider A1C goals, kidney function, cardiovascular history, weight goals, other medications, age, injection preference, and coverage.

Which Medication Has a Cardiovascular Indication?

Ozempic injection reduces the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Ozempic tablets reduce that risk in adults with type 2 diabetes who are at high risk for those events.

Wegovy injection and tablets reduce the risk of cardiovascular death, nonfatal heart attack, or nonfatal stroke in adults with established cardiovascular disease and obesity or overweight.

Mounjaro and Zepbound may have cardiovascular research data, but a study result is not the same as an FDA-approved indication. The current product label should be used when describing what a medication is officially approved to do.

Which Medication Has a Kidney-Disease Indication?

Ozempic injection is approved to reduce the risk of sustained decline in estimated glomerular filtration rate, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.

That does not mean the other medications have no effects on kidney outcomes — it means Ozempic injection currently carries this specific FDA-approved risk-reduction indication.

Which Medication Is Approved for Sleep Apnea?

Zepbound is approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity. This is a treatment indication, not simply a statement that weight reduction may improve sleep apnea. Patients still need appropriate evaluation, monitoring, and treatment planning for obstructive sleep apnea.

Which Medication Is Approved for MASH?

Wegovy injection is approved for adults with noncirrhotic MASH and moderate to advanced fibrosis consistent with F2 to F3 fibrosis. This indication received accelerated approval based on improvements in MASH and fibrosis. Continued approval may depend on verification of clinical benefit in a confirmatory trial.

Can These Medications Be Taken Together?

No combination among these four should be started without explicit specialist direction, and their labels advise against combining products that contain the same active ingredient or using them with another GLP-1 receptor agonist.

Do not combine Ozempic with Wegovy, Mounjaro with Zepbound, semaglutide with tirzepatide, or any of these products with another GLP-1 medication unless a qualified prescriber has specifically evaluated the situation. Duplicate incretin therapy may increase adverse effects without an established benefit.

What Side Effects Do They Share?

Common side effects frequently include nausea, diarrhea, vomiting, constipation, abdominal discomfort or pain, indigestion, decreased appetite, and reflux, belching, or bloating.

Side effects often appear or worsen during dose escalation. Starting at a low dose and increasing gradually helps reduce gastrointestinal intolerance, but it does not eliminate it.

Contact a healthcare professional for persistent vomiting, inability to keep fluids down, signs of dehydration, severe abdominal pain, symptoms of gallbladder disease, or another concerning reaction.

Important Safety Warnings

All four products carry a boxed warning about thyroid C-cell tumors observed in rodents. It is not known whether these medications cause medullary thyroid carcinoma in humans. They are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Other important warnings and precautions may include acute pancreatitis, gallbladder disease, severe gastrointestinal reactions, acute kidney injury from volume depletion, hypoglycemia when combined with insulin or an insulin secretagogue, diabetic-retinopathy complications in susceptible patients, serious hypersensitivity reactions, delayed gastric emptying, and pulmonary aspiration risk during anesthesia or deep sedation.

Patients should tell the surgical or anesthesia team that they use a GLP-1 or GIP/GLP-1 medication before a planned procedure.

A Special Consideration With Tirzepatide and Oral Birth Control

Mounjaro and Zepbound can reduce the effectiveness of oral hormonal contraceptives because tirzepatide delays gastric emptying.

Their labels advise patients using oral hormonal contraception to switch to a non-oral method or add a barrier method for four weeks after starting tirzepatide and after each dose increase. This is an important counseling difference between tirzepatide and semaglutide products.

Can These Medications Be Used During Pregnancy?

These medications are not used for routine weight reduction during pregnancy, and the labels warn of potential fetal harm.

Semaglutide has a long half-life. For patients receiving Ozempic or Wegovy, labeling advises discontinuation at least two months before a planned pregnancy.

Anyone who is pregnant, planning pregnancy, breastfeeding, or using contraception should discuss treatment timing with the prescriber.

How Does Insurance Decide Which One to Cover?

Insurance coverage is often diagnosis-specific. A plan may ask whether the patient has type 2 diabetes, whether the medication is being requested for chronic weight management, whether the patient meets BMI criteria or has a qualifying weight-related condition, whether cardiovascular or kidney disease is documented, whether a preferred medication was tried, whether weight-management medication is excluded from the benefit, and whether the patient has shown a positive response for continuation.

A diabetes diagnosis does not automatically create coverage for Wegovy or Zepbound. Likewise, obesity does not automatically create coverage for Ozempic or Mounjaro. The pharmacy claim, prescription diagnosis, prior authorization, and medical records must point in the same direction.

Which One Is Best?

There is no universal winner. A clinician may lean toward one product because of type 2 diabetes, obesity or overweight, cardiovascular disease, chronic kidney disease, obstructive sleep apnea, MASH, patient age, tablet versus injection preference, previous treatment response, side-effect history, pregnancy plans, other medications, or insurance coverage and cost.

The best medication is the one that has an appropriate indication, acceptable safety profile, practical administration plan, and realistic access for the individual patient.

Try the Interactive Comparison Tool

Filter by treatment goal — diabetes, weight management, cardiovascular, kidney, sleep apnea, MASH, pediatric, or tablet option — and build a side-by-side comparison of any two or more medications.

Questions to Ask Your Prescriber or Pharmacist

• Which diagnosis are we treating?
• Is this product FDA-approved for that diagnosis?
• Why are you recommending this brand instead of the related brand?
• Do I have a condition that makes one option more appropriate?
• What dose will I start with, and how quickly will it increase?
• What side effects should prompt a call?
• Could this interact with insulin, sulfonylureas, or oral birth control?
• What should I do before surgery or a procedure?
• Does my insurance require prior authorization?
• What measurements will be used to determine whether treatment is working?

Frequently Asked Questions